HOME >> MEDICINE >> NEWS
GlaxoSmithKline's Havrix now approved for use in children aged 12 months and older

Philadelphia, PA October 18, 2005 GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) approved the expanded use of Havrix(R) (hepatitis A vaccine, inactivated) for the prevention of hepatitis A in children aged 12 months and older. Havrix was previously approved by the FDA for use in children ages two through 18 years. This expanded indication will allow healthcare practitioners to vaccinate younger children against hepatitis A with Havrix and may help to further reduce the incidence of hepatitis A in the United States, particularly among young children who often transmit the disease.

"The expanded indication of Havrix marks an important milestone in the fight against hepatitis A in the United States," said William P. Hitchcock, M.D., of the American Board of Pediatrics, La Jolla, California. "Immunizing children under age two helps protect a very vulnerable population that often does not show symptoms of the disease but frequently spreads it to other children and family members."

Havrix for the Prevention of Hepatitis A in Children Aged 12 Months and Older
The FDA approved the expanded use of Havrix in children to 12 months and older on the basis of a pivotal trial which studied the administration of Havrix in children in the United States and Australia. The prospective, open, comparative, multi-center clinical trial involved over 1,000 healthy children and showed Havrix given to children down to the age of 11 months to be comparable to Havrix given to children approximately two years of age with regard to safety and immunogenicity. The study also showed that Havrix can be given concomitantly with OMNIHIBTM [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)], also called Hib conjugate vaccine (PRP-T).

Each subject was enrolled in one of five groups according to their age and previous vaccination history and vaccinated with either Havrix alone or Havrix with Infanrix (D
'"/>


18-Oct-2005


Page: 1 2 3

Related medicine news :

1. Did drug reps encourage doctors to prescribe gabapentin for nonapproved uses?
2. NIH scientists honored for FDA-approved cervical cancer vaccine breakthrough
3. Previously approved drugs may be helpful in fatal pediatric disorder
4. Shires DAYTRANA(TM) transdermal patch approved by FDA for treatment of ADHD
5. Higher dose formulation of FOSRENOL approved to reduce serum phosphorus in esrd patients
6. FDA approved ROZEREM (ramelteon)
7. Cedars-Sinais live donor liver transplant program receives unos-approved designation
8. Many drugs prescribed for chronic insomnia are not approved for that purpose
9. Sildenafil (Viagra) approved for treatment of pulmonary arterial hypertension (PAH) as Revatio
10. Chinese children with hearing devices benefit from new speech test
11. Seat belt injuries could signal more serious trauma in children

Post Your Comments:
(Date:3/28/2015)... (PRWEB) March 28, 2015 Pitching speed, player’s ... history of shoulder and elbow injuries, according to new research ... ( AOSSM ) Specialty Day. , “Our findings indicate that ... 20% increase in likelihood of a history of injury, a ... a 12% increase likelihood of a history of injury, and ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... hip injuries is a growing field in orthopaedic medicine. ... with labral tear to confirm the pain etiology, research ... Medicine’s ( AOSSM ) Specialty Day suggests that pain ... outcomes following arthroscopic hip surgery. , “Our study ...
(Date:3/28/2015)... 2015 Early surgery may not be ... AC joint injuries, according to new research from Tripler ... American Orthopaedic Society for Sports Medicine’s ( AOSSM ) ... when surgery was not performed. , The final study ... treatment and 17 receiving non-surgical therapy. Of the non-surgery ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Andrew Hawley of ... 1960's Who psychedelic concert posters. The Who and the Doors ... on August 2, 1968. According to Hawley, “The Who toured ... concert halls and college campuses. Perhaps the most famous Who ... Jim Morrison and the Doors on August 2, 1968 at ...
(Date:3/28/2015)... 28, 2015 Aureus Medical Group ... including physical therapy jobs, has announced that it ... Physical Therapy Association Annual Conference to be held ... Hotel in Columbus, OH. , The OPTA ... exhibits with products and services. , Representatives ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
(Date:3/27/2015)... , March 27, 2015 Report ... for leading ophthalmic drug companies  What does ... pharma ophthalmic industry ? Visiongain,s brand new report shows ... and prospects there. Our 242-page report provides ... areas in the industry and the future market prospects. ...
(Date:3/27/2015)... , March 27, 2015 As ... shipments of incontinence devices for women. ... the most gratifying part is the hundreds of ... women whose lives have been positively impacted by ... of InControl. InControl recently released Apex, ...
(Date:3/27/2015)... Mass. , March 27, 2015 /PRNewswire/ ... and privately-held MirImmune LLC, today announced that ... agreement to RXi,s novel and proprietary sd-rxRNA® ... cancer immunotherapies. The collaboration has the potential ... patient friendly cancer treatments that could be ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
Cached News: